SEC Tracker
Get the app
PRLD · XBRL financial data

Prelude Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (PRLD's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers————3,0004,000*006,5005,640*4,5805,704
Research and development26,26130,332*27,40929,50929,45731,620*28,81625,78421,70817,992*13,60116,131
General and administrative7,1247,047*6,9347,6557,9196,211*5,7906,4105,2104,996*5,1565,027
Total operating expenses33,38537,379*34,34337,16437,37637,831*34,60632,19426,91822,988*18,75721,158
Operating income (loss)(33,385)(37,379)*(34,343)(37,164)(34,376)(33,831)*(34,606)(32,194)(20,418)(17,348)*(14,177)(15,454)
Other income (expense)2,7774,304*2,9122,4242,1055,100*2,521963693891*3,7921,533
Income tax expense (benefit)—————year only———year only——
Net income (loss)(30,608)(33,075)*(31,431)(34,740)(32,271)(28,731)*(32,085)(31,231)(19,725)(16,457)*(10,385)(13,921)
Earnings per share, basic USD per share(0.45)(0.48)*(0.42)(0.46)(0.43)(0.38)*(0.42)(0.41)(0.26)(0.21)*(0.13)(0.14)
Earnings per share, diluted USD per share(0.45)(0.48)*(0.42)(0.46)(0.43)(0.38)*(0.42)(0.41)(0.26)(0.21)*(0.13)(0.14)
Weighted average shares, basic thousands of shares67,64069,491*75,73675,76275,85675,868*75,98675,99476,13279,681*82,52098,389
Weighted average shares, diluted thousands of shares67,64069,491*75,73675,76275,85675,868*75,98675,99476,13279,681*82,52098,389

Balance sheet

CSV

Fiscal quarters (PRLD's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents15,89625,29124,70727,82811,13412,47440,26925,75247,53235,25621,75626,329
Marketable securities214,610207,644177,217152,016142,492121,14058,80547,4647,42567,95859,798125,428
Prepaid and other current assets4,4102,6543,4422,8702,7612,2813,3293,6603,3732,4783,0393,141
Total current assets234,916235,589205,366182,714156,387135,895102,40376,87658,330105,69284,593154,898
Property and equipment, net6,6187,3257,2947,5547,2026,7676,3885,9565,5315,1134,7224,397
Right-of-use asset46430,41230,10729,57429,18228,69928,31527,93227,54927,16526,77826,389
Total assets258,511277,665247,106224,291197,220175,515141,260114,91894,755141,315119,642189,363
Accounts payable5,1704,5805,3086,1705,9217,7325,8314,9622,5333,9832,0692,032
Accrued liabilities11,24815,76810,14711,42613,57915,20911,30313,23512,93012,5335,9387,983
Total current liabilities16,89321,82917,64323,33522,22425,64119,78720,90818,19052,99441,72038,042
Lease liability, non-current—15,40715,45215,46515,41215,32515,26715,20615,12715,04514,96014,871
Total liabilities20,25440,57536,37242,01540,78944,05638,08239,08036,22172,67859,45955,630
Accumulated deficit(423,315)(456,390)(487,821)(522,561)(554,832)(583,563)(615,648)(646,879)(666,604)(683,061)(693,446)(707,367)
Total stockholders' equity238,257237,090210,734182,276156,431131,459103,17875,83858,53468,63760,183133,733
Total liabilities and equity258,511277,665247,106224,291197,220175,515141,260114,91894,755141,315119,642189,363
Common shares outstanding (cover page) thousands of shares54,82654,92154,93055,02455,03555,15556,46056,60062,86563,00279,64579,803

Cash flows

CSV

Fiscal quarters (PRLD's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(30,608)(33,075)*(31,431)(34,740)(32,271)(28,731)*(32,085)(31,231)(19,725)(16,457)*(10,385)(13,921)
Stock-based compensation6,715*5,912*5,5476,098*5,926*3,774*3,8323,814*2,423*1,844*2,0002,027*
Depreciation and amortization279*331*426452*405*489*435433*425*418*391353*
Net cash from operating activities(25,683)*(23,578)*(31,791)(23,057)*(27,296)*(20,744)*(34,231)(26,075)*(19,115)*23,119*(21,685)(15,574)*
Purchases of property and equipment591*1,129*289359*63*53*4720*0*0*00*
Net cash from investing activities15,045*7,736*31,22126,119*10,733*22,118*62,18611,521*40,091*(60,339)*8,499(65,503)*
Net cash from financing activities88*25,237*(14)59*(131)*(34)*(160)37*(5)*24,944*(314)85,820*
Net change in cash(10,550)*9,395*(584)3,121*(16,694)*1,340*27,795(14,517)*20,971*(12,276)*(13,500)4,743*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Prelude Therapeutics26,3295,704(15,574)*79.8M9.7 quarters 10-QJun 30, 2026
Edesa Biotech10,300not reported(3,083)*9.6M3.3 quarters 10-QJun 30, 2026
X4 Pharmaceuticals185,8012,879(20,186)*102.1M9.2 quarters 10-QSep 30, 2026
Akari Therapeutics7,694not reported(3,109)*155.8B2.5 quarters 10-QJun 30, 2026
GeoVax Labs3,143not reported(3,658)*7.4M0.9 quarters 10-QJun 30, 2026
ProPhase Labs201,011(78)*15.6M0.3 quarters 10-QJun 30, 2026
Pluri3,529335*(4,443)*12.3M0.8 quarters 10-KJun 30, 2026
Earth Science Tech6319,026707287.6M— 10-QJun 30, 2026
CalciMedica18,617not reported(4,620)*34.1M4.0 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.